Company news

Cardiol Therapeutics Inc. news in 2024

Cardiol Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

October 22, 2024

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

October 11, 2024

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

October 10, 2024

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

October 9, 2024

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

October 8, 2024

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

September 24, 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

September 10, 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

June 27, 2024

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4: 30 p.m. EDT

June 25, 2024

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

June 13, 2024

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

June 11, 2024

Sector Spotlight: Orphan Drug Developers With Significant Upside

June 3, 2024

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

May 14, 2024

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

April 2, 2024

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

February 21, 2024

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

February 15, 2024

Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market

January 24, 2024

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

January 9, 2024

Decks in 2024